deltatrials
Terminated PHASE2 INTERVENTIONAL 5-arm NCT04103645

Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

A 2-tiered, Phase 2, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) in the Treatment of Anemic Patients With Philadelphia Chromosome-negative MPNs (Ph-neg MPNs)

Sponsor: Weill Medical College of Cornell University

Conditions Myeloproliferative Neoplasm
Interventions Vactosertib
Updated 13 times since 2019 Last updated: Jun 12, 2025 Started: Nov 22, 2019 Primary completion: Jul 10, 2024 Completion: Jul 10, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low accrual

Other terminated trials from Weill Medical College of Cornell University

See all terminations from Weill Medical College of Cornell University

Listed as NCT04103645, this PHASE2 trial focuses on Myeloproliferative Neoplasm and remains terminated or withdrawn. Sponsored by Weill Medical College of Cornell University, it has been updated 13 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~May 2020 · 4 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jan 2022 · 11 months · monthly snapshot~Jan 2022 – ~Jan 2023 · 12 months · monthly snapshot~Jan 2023 – ~Dec 2023 · 11 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Aug 2025 · 8 months · monthly snapshot~Aug 2025 – present · 11 months · monthly snapshot

Change History

13 versions recorded

  1. Aug 2025 — Present [monthly]

    Terminated PHASE2

  2. Dec 2024 — Aug 2025 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  3. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Dec 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 8 earlier versions

  1. Jan 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  2. Jan 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  3. Feb 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  4. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  5. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Jan 2020 — May 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Nov 2019 — Jan 2020 [monthly]

    Not Yet Recruiting PHASE2

  8. Oct 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Weill Medical College of Cornell University
Data source: Weill Medical College of Cornell University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations